JPMorgan Chase & Co. Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by JPMorgan Chase & Co. from $168.00 to $200.00 in a research report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the subject of a number of other research reports. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald boosted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Trading Down 2.5 %

NASDAQ ASND opened at $164.65 on Tuesday. The stock’s 50 day moving average is $139.43 and its two-hundred day moving average is $135.09. The company has a market capitalization of $9.99 billion, a price-to-earnings ratio of -23.19 and a beta of 0.62. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Loomis Sayles & Co. L P raised its position in shares of Ascendis Pharma A/S by 35.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after acquiring an additional 48,120 shares during the last quarter. Valence8 US LP bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $685,000. Rice Hall James & Associates LLC raised its position in shares of Ascendis Pharma A/S by 2.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after acquiring an additional 3,274 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of Ascendis Pharma A/S by 42.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after acquiring an additional 5,371 shares during the last quarter. Finally, Maven Securities LTD bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $7,466,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.